IP Library Granted Patent US 9,180,039
Granted Patent B2
US 9,180,039 · App. 13/294,091 · Granted Nov 10, 2015

Intrauterine device

Inventors: Michael G. Tal (Savyon, IL); Patrick N. Gutelius (Monroe, CT); Mark J. DeBisschop (Harwinton, CT); Oleg Shikhman (Trumball, CT); Pasquale Patrizio (Guilford, CT); Bob H. Katz (San Jose, CA)
Assignees: Yale University; ContraMed, LLC
A61F6/144A61F6/142A61F6/18A61F6/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,180,039
App. No.
13/294,091
Granted
Nov 10, 2015
Kind
B2
Abstract

An intrauterine device for applying force to a wall of a uterus to promote contraception without blocking the fallopian tubes may include an elongate member formed of a resilient material and having a default expanded configuration and a spring portion disposed approximately at a midpoint between two ends of the elongate member. The IUD may also include two tissue contact members, one tissue contact member disposed at one of the two ends of the elongate member and the other tissue contact member disposed at the other end. The tissue contact members may generate a laterally directed force against the wall of the uterus when the intrauterine device assumes its default expanded configuration.

Claims (26)

1. An intrauterine device for applying force to a wall of a uterus to promote contraception without blocking the fallopian tubes, the intrauterine device comprising:

an elongate member formed of Nitinol, having a diameter between 0.010 inch and 0.025 inch, and having a default expanded configuration and a spring portion disposed approximately at a midpoint between two ends of the elongate member; wherein the elongate member comprises two elongate members that diverge away from one another; and

two tissue contact members, one of which is disposed at one end of the elongate member and the other of which is disposed at the other end, wherein each tissue contact member comprises a non-porous material and has a surface area of at least 30 mm squared,

wherein the intrauterine device has a width measured from a tip of one tissue contact member to a tip of the other tissue contact member of at least 40 mm in its expanded configuration outside the uterus.

2. An intrauterine device as in claim 1 , wherein the default expanded configuration of the elongate member comprises a V-shape, wherein the spring portion is disposed at a vertex of the V-shape, and wherein the elongate member curves laterally from the spring portion to each of the two ends.

3. An intrauterine device as in claim 2 , wherein a height of the intrauterine device measured from a bottom of the spring portion to a top of the tissue contact members is at least about 25 mm.

4. An intrauterine device as in claim 2 , wherein the elongate member further

includes at least two bends configured to reduce the amount of laterally directed force, one bend disposed between the spring portion and one of the two ends, and the other bend disposed between the spring portion and the other end.

5. An intrauterine device as in claim 1 , wherein the tissue contact members generate a total, laterally directed force against the wall of the uterus of between 0.002 pounds-force and 0.025 pounds-force when the intrauterine device assumes its default expanded configuration within the uterus.

6. An intrauterine device as in claim 5 , wherein the tissue contact members generate a total, laterally directed force against the wall of the uterus of between 0.002 pounds-force and 0.015 pounds-force when the intrauterine device assumes its default expanded configuration within the uterus.

7. An intrauterine device as in claim 1 , further comprising a substance disposed in an inner channel in the elongate member or in or on the tissue contact members.

8. An intrauterine device as in claim 7 , wherein the substance is selected from the group consisting of hormones, spermicides, copper and therapeutic agents.

9. An intrauterine device as in claim 1 , wherein the spring portion comprises a spring having at least one coil formed in the elongate member.

10. An intrauterine device as in claim 1 , wherein the intrauterine device is compressible into a collapsed configuration for positioning within a delivery sheath having an inner diameter of no more than 3.9 mm.

11. An intrauterine device as in claim 1 , wherein the elongate member has a diameter of between 0.014 inch and 0.015 inch.

12. An intrauterine device as in claim 1 , further comprising at least one additional tissue contact member for contacting the uterine wall at a different location.

13. An intrauterine device as in claim 12 , wherein the additional tissue contact member comprises at least one fundus contact member coupled with at least one of the two tissue contact members via an additional Nitinol elongate member for contacting a fundus of the uterus.

14. A system for promoting contraception without blocking the fallopian tubes by applying force to a wall of a uterus, the system comprising:

an elongate, at least partially hollow delivery device having an outer diameter suitable for passing through a cervix;

an intrauterine device preloaded into the delivery device, wherein the intrauterine device comprises:

an elongate member formed of Nitinol, having a diameter between 0.010 inch and 0.025 inch, a compressed configuration for residing in the delivery device, a default expanded configuration, and a spring portion disposed approximately at a midpoint between two ends of the elongate member; wherein the elongate member comprises two elongate members that diverge away from one another; and

two tissue contact members, one of which is disposed at one end of the elongate member and the other of which is disposed at the other end, wherein each tissue contact member comprises a non-porous material and has a surface area of at least 30 mm squared,

wherein the intrauterine device has a width measured from a tip of one tissue contact member to a tip of the other tissue contact member of at least 40 mm in its expanded configuration outside the uterus.

15. A system as in claim 14 , further comprising a substance for delivering to the uterus through the intrauterine device.

16. A system as in claim 15 , wherein the substance is selected from the group consisting of hormones, spermicides, copper and therapeutic agents.

17. A system as in claim 14 , wherein the delivery device has an inner diameter of no more than 3.9 mm.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2018
From: CONTRAMED, LLC
To: SEBELA VLC LIMITED
Reel/Frame 046742/0265 →
SECURITY INTEREST Recorded Jul 12, 2018
From: SEBELA VLC LIMITED
To: NOVA-QUEST CO-INVESTMENT FUND VII, L.P.
Reel/Frame 046331/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2016
From: TAL, MICHAEL G
To: YALE UNIVERSITY
Reel/Frame 040332/0587 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF ASSIGNEE AND ONE ASSIGNOR PREVIOUSLY RECORDED ON REEL 027419 FRAME 0754. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Oct 12, 2016
From: GUTELIUS, PATRICK N; DEBISSCHOP, MARK J; SHIKHMAN, OLEG; PATRIZIO, PASQUALE; KATZ, BOB H
To: CONTRAMED, LLC
Reel/Frame 040332/0914 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2011
From: TAL, MICHAEL G.; GUTELIUS, PATRICK N.; DEBISSCHOP, MARK J.; SHIKHMAN, OLEG; PATRIZIO, PASQUALE; KATZ, BOB H.
To: YALE UNIVERSITY
Reel/Frame 027419/0754 →
Continuity (2)
Continuation In Part 12856876 · Aug 16, 2010
Related Publication 20120097172A1 · Apr 26, 2012